David Ricks “We have said it’s not for us right now,” said Ricks. Reuters noted that Ricks is much bolder than his predecessors in terms of acquisitions, after years when Lilly tried to make ...

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Now, though, Lilly chief executive officer David Ricks says he is considering expanding the vial offering. Lilly has been offering the vials only to patients paying on their own without insurance ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Buried in the news from last month was an interesting nugget posted by Fierce Pharma: “Following a dinner at Trump’s Mar-a-Lago estate last week, Eli Lilly CEO David Ricks pointed to raising ...